03/27/2026
For longevity science, the goal isn't just a longer life, but a better one. Yet how the field talks about that goal, to the public and to itself, is still a subject of debate. This panel from the Longevity Biomarkers Summit at Infinita City, Roatán digs into that question and more.
Panelists:
Tina Woods | Collider Health
Eric Verdin| CEO, Buck Institute for Research on Aging
Jasmine Smith | CEO, Rejuve.AI
Keith Comito| CEO & President, Lifespan Research Institute
Moderated by: Macsue Jacques, Decoding Longevity Podcast
Highlights:
► Health span vs. lifespan: do we actually need to choose?
► Is the longevity field "shooting ahead of its skis" and ways the field can earn public trust.
► What are the ways we can be ambitious in terms of advocating for maximal life extension, together with healthspan.
► The systemic, political, and economic barriers standing between us and longer, healthier lives, and ways to potentially overcome them.
► Why biomarkers might be the field's most underrated tool right now.
► GLP-1s, epigenetic reprogramming, Alzheimer's light therapy, and the one intervention that might already be free.
For longevity science, the goal isn't just a longer life, but a better one. Yet how the field talks about that goal, to the public and to itself, is still a ...